Antonia D'ANiello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antonia D'ANiello has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Concetta Avitabile
Institute of Crystallography, National Research Council of Italy, URT Caserta, via Vivaldi 43, 81100 Caserta, Italy
2 shared publications - Maria Moccia
Institute of Crystallography, National Research Council of Italy, Strada Provinciale 35d, 9, Montelibretti, 00010 Rome, Italy
2 shared publications - Michele Saviano
Institute of Crystallography, CNR, Via Vivaldi 43, 81100, Caserta, Italy
2 shared publications - Annalisa Masi
Istituto di Cristallografia, Consiglio Nazionale delle Ricerche, Via Salaria km 29.300, 00015 Monterotondo, Italy
1 shared publication - Giovanni del Monaco
Institute of Crystallography, National Research Council of Italy, URT Caserta, via Vivaldi 43, 81100 Caserta, Italy
1 shared publication Maria Teresa Cerasa
Dipartimento di Scienze e Tecnologie Chimiche Università di Roma Tor Vergata via della Ricerca scientifica 1 Roma 00133 Italy
1 shared publication
Latest Publications
- Open Access
- 5 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1565
Peptide Nucleic Acids (PNAs) in Antimicrobial Therapy: A Next Generation Strategy
The global rise in antimicrobial resistance (AMR) demands innovative strategies beyond traditional antibiotics. Peptide Nucleic Acids (PNAs), synthetic DNA analogues with peptide-like backbones, act as thermically, chemically, and enzymatically stable sequence-specific agents capable of silencing essential bacterial genes. Through antisense mechanisms, PNAs bind bacterial mRNA or rRNA, blocking translation or ribosome assembly and thereby inducing species-specific growth inhibition. Their programmable design enables precise targeting of multidrug-resistant pathogens while sparing commensal microbiota. Recent advances, including γ-modified backbones, cationic substitutions, and delivery platforms such as cell-penetrating peptides (CPPs), dendron conjugates, and nanoparticles, have improved solubility, stability, and cellular uptake. Studies show promising in vitro and, albeit less frequently, in vivo efficacy against both Gram-positive and Gram-negative bacteria, often with synergistic activity when combined with conventional antibiotics. Although challenges remain in delivery and large-scale production, PNAs represent a promising class of antimicrobials to combat AMR through targeted gene inhibition.
- 5 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1565
Open AccessPeptide Nucleic Acids (PNAs) in Antimicrobial Therapy: A Next Generation Strategy
The global rise in antimicrobial resistance (AMR) demands innovative strategies beyond traditional antibiotics. Peptide Nucleic Acids (PNAs), synthetic DNA analogues with peptide-like backbones, act as thermically, chemically, and enzymatically stable sequence-specific agents capable of silencing essential bacterial genes. Through antisense mechanisms, PNAs bind bacterial mRNA or rRNA, blocking translation or ribosome assembly and thereby inducing species-specific growth inhibition. Their programmable design enables precise targeting of multidrug-resistant pathogens while sparing commensal microbiota. Recent advances, including γ-modified backbones, cationic substitutions, and delivery platforms such as cell-penetrating peptides (CPPs), dendron conjugates, and nanoparticles, have improved solubility, stability, and cellular uptake. Studies show promising in vitro and, albeit less frequently, in vivo efficacy against both Gram-positive and Gram-negative bacteria, often with synergistic activity when combined with conventional antibiotics. Although challenges remain in delivery and large-scale production, PNAs represent a promising class of antimicrobials to combat AMR through targeted gene inhibition.
- Open Access
- 21 May 2025
- Published by Wiley in Chemistry – A European Journal
- Vol. 31 (34) , e202500469
Recent Cutting‐Edge Technologies for the Delivery of Peptide Nucleic Acid
Peptide nucleic acids (PNAs) have garnered significant attention due to their enhanced chemical, physical, and binding properties in comparison to natural nucleic acids. This prompted their application in antigene/antisense approach, assigning them a pivotal role in gene editing and, more recently, showing their potential as “bilingual” molecules being able “to speak” both nucleic acid and protein language. However, to expand the applications of PNAs in therapy, the challenge of effectively delivering PNAs to cells needs to be addressed. Among several delivery approaches employed so far, the nanotechnology‐based ones showed great potential. In this review, we provide an overview of the latest in the field (2019 to present), beginning from peptide‐based delivery systems, as well as cutting‐edge approaches involving nanoparticles, liposomes, and calixarene, showing how they have inspired the development of smarter delivery approaches to boost PNAs applications.
- 21 May 2025
- Published by Wiley in Chemistry – A European Journal
- Vol. 31 (34) , e202500469
Open AccessRecent Cutting‐Edge Technologies for the Delivery of Peptide Nucleic Acid
Peptide nucleic acids (PNAs) have garnered significant attention due to their enhanced chemical, physical, and binding properties in comparison to natural nucleic acids. This prompted their application in antigene/antisense approach, assigning them a pivotal role in gene editing and, more recently, showing their potential as “bilingual” molecules being able “to speak” both nucleic acid and protein language. However, to expand the applications of PNAs in therapy, the challenge of effectively delivering PNAs to cells needs to be addressed. Among several delivery approaches employed so far, the nanotechnology‐based ones showed great potential. In this review, we provide an overview of the latest in the field (2019 to present), beginning from peptide‐based delivery systems, as well as cutting‐edge approaches involving nanoparticles, liposomes, and calixarene, showing how they have inspired the development of smarter delivery approaches to boost PNAs applications.